High–quality iPSC derived lines from patient and control human donors
Commercially available and consented iPSC lines
We have a commercial library of 70 iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with:
- Alzheimer’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Frontotemporal Dementia
- Friedreich’s Ataxia
- Huntington’s Disease
Our axoLinesTM iPSCs are used for axoServicesTM custom lab services, made-to-order axoCellsTM projects and specific licensing arrangements.
The lines are derived from patient and healthy samples. To ensure high-quality cells that more closely mimic in vivo physiology, we extract fibroblasts or PBMCs from consenting donors and reprogram them into iPSCs, guided by our decades of scientific experience.
How axoLinesTM can support your research:
- 70 lines from a wide range of healthy (10) and patient (60) donors
- Diverse library including sibling and familial partners
- 50:50 split of male/female donors to address sex disparities in biopharma research
- Our reputation for quality has led to collaboration with leading research institutes and top ten biopharma
axoLinesTM
| Disease | No. of Line | Specific Conditions | Additional Information/Mutations |
| ALS | 5 | 2 x symptomatic (1 x TDP43, 1 x SOD1), 1 x C9ORF72+ but asymptomatic | |
| Ataxia | 16 | Spinocerebellar Ataxia (10) | 3 x SCA2, 5 x SCA3, 1 x SCA6, 1 x SCA7 |
| Friedreich’s Ataxia (6) | 4 x symptomatic (FXN), 1 x familial (FXN) 1 x healthy with normal FXN | ||
| Dementia | 18 | Alzheimer’s (7) | 1 x APOE3/E3, 2 x APOE3/E4, 1 x APOE4/E4, 3 x PSEN1 (A246L, M146 and L286V) |
| Frontotemporal Dementia (9) | 3 x MAPT, 2 x Progranulin, 1 x TARDBP, 2 x VCP, and 1 x “at risk” patient. | ||
| Behavioural Variant Frontotemporal Dementia (bvFTD) (3) | 3 x MAPT | ||
| Huntington’s | 5 | HTT including one asymptomatic carrier | |
| Parkinson’s | 14 | Including 5 x Ataxin-3, 2 x PINK1 & PARK2, 1 x PINK1 & PARKIN, 1 x PINK1, 3 x SNCA, 2 x LRRK2 |
Highlights
- 70 characterised lines from patient and control donors
- 50:50 split of male/female donors
- 10 healthy (control) donors
- Human iPSCS from eight main therapy areas
